Title
The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation.

Permalink
https://escholarship.org/uc/item/4vz465dt

Authors
Faust, Tyler B
Li, Yang
Bacon, Curtis W
et al.

Publication Date
2018-05-30

DOI
10.7554/elife.31879

Peer reviewed
The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation

Tyler B Faust¹, Yang Li¹, Curtis W Bacon², Gwendolyn M Jang³,⁴, Amit Weiss¹, Bhargavi Jayaraman¹, Billy W Newton³,⁴, Nevan J Krogan³,⁴, Iván D’Orso², Alan D Frankel¹*

¹Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States; ²Department of Microbiology, University of Texas Southwestern Medical Center, Dallas, United States; ³Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States; ⁴J David Gladstone Institutes, San Francisco, United States

Abstract

The HIV-1 Tat protein recruits a ubiquitin ligase to reorganize the 7SK snRNP for transcriptional activation. Tat binds additional host factors, but it is unclear how they regulate RNAP II elongation. Here, we identify the cytoplasmic ubiquitin ligase UBE2O as critical for Tat transcriptional activity. Tat hijacks UBE2O to ubiquitinate the P-TEFb kinase inhibitor HEXIM1 of the 7SK snRNP, a fraction of which also resides in the cytoplasm bound to P-TEFb. HEXIM1 ubiquitination sequesters it in the cytoplasm and releases P-TEFb from the inhibitory 7SK complex. Free P-TEFb then becomes enriched in chromatin, a process that is also stimulated by treating cells with a CDK9 inhibitor. Finally, we demonstrate that UBE2O is critical for P-TEFb recruitment to the HIV-1 promoter. Together, the data support a unique model of elongation control where non-degradative ubiquitination of nuclear and cytoplasmic 7SK snRNP pools increases P-TEFb levels for transcriptional activation.

DOI: https://doi.org/10.7554/eLife.31879.001

Introduction

The advent of genome-wide methods to interrogate transcription has shown that many genes in higher eukaryotes contain stably paused RNAP II molecules immediately downstream of transcription start sites (Core et al., 2008; Henriques et al., 2013; Kwak and Lis, 2013; Rahl et al., 2010; Zeitlinger et al., 2007). The release of RNAP II into productive elongation is controlled by the kinase positive transcription elongation factor b (P-TEFb), composed of cyclin T1 (CCNT1) and cyclin-dependent kinase 9 (CDK9) subunits (Kwak and Lis, 2013; Marshall and Price, 1995). P-TEFb hyper-phosphorylates DRB sensitivity inducting factor (DSIF), negative elongation factor (NELF), and the C-terminal domain of RNAP II, resulting in a processive polymerase (Czudnochowski et al., 2012; Yamaguchi et al., 1999). Numerous cellular proteins interact with P-TEFb to relieve pausing, including bromodomain-containing protein 4 (BRD4) (Yang et al., 2005), Mediator (Takahashi et al., 2011), nuclear factor (NF)-κB (Barboric et al., 2001), and c-Myc (Eberhardy and Farnham, 2002). The human immunodeficiency virus-1 (HIV-1) transcription factor, Tat, also interacts with P-TEFb to activate a paused polymerase at the viral promoter (Feinberg et al., 1991; Wei et al., 1998).

P-TEFb activity is controlled by sequestration into the inhibitory 7SK small nuclear ribonucleoprotein (snRNP) complex (Nguyen et al., 2001; Yang et al., 2001). In this complex, hexamethylene bisacetamide inducible 1 (HEXIM1) inhibits the kinase activity of CDK9 in a 7SK snRNA-dependent manner (Michels et al., 2004), while the 7SK snRNA methyl phosphate capping enzyme (MEPCE)
and La-related protein 7 (LARP7) stabilize the 7SK snRNA by adding a 5’ methylphosphate cap or binding to the 3’ poly(U) tail of the RNA, respectively (He et al., 2008). Multiple signaling pathways regulate the association of P-TEFb with the 7SK snRNP, tuning the required levels of active kinase in the cell (Chen et al., 2008; Liu et al., 2014). We have previously shown that 7SK snRNP-inhibited P-TEFb is recruited to the HIV-1 promoter (D’Orso and Frankel, 2010), where Tat activates transcription elongation by displacing the inhibitory subunits through binding of the nascently transcribed transactivation response element (TAR) RNA. Supporting this model of activation, recent genome-wide studies have revealed that snRNP-bound P-TEFb occupies the majority of promoters that display RNAP II pausing (Ji et al., 2013; McNamara et al., 2016). In this context, the splicing protein SC35 appears to act analogously to Tat by releasing the 7SK snRNP in a nascent RNA-binding-dependent step (Ji et al., 2013).

Ubiquitination is a post-translational modification in which the 76 amino acid protein ubiquitin becomes covalently attached via its C-terminus to a primary amine on a substrate protein. Beyond its well-known function as a signal for degradation, ubiquitination has emerged as a major signaling pathway in the cell, especially in transcription. As an example, mono-ubiquitination of histone H2B is associated with transcriptionally active chromatin and regulates subsequent histone modifications (Hammond-Martel et al., 2012). Ubiquitination of other transcription factors, including p53 and Myc, can lead to proteasomal degradation (Haupt et al., 1997; Kim et al., 2003), stabilization (Popov et al., 2010), or re-localization (Le Cam et al., 2006), underscoring the diversity of regulatory mechanisms for ubiquitination in transcriptional control.

Here, we report the identification of ubiquitin conjugating enzyme E2 O (UBE2O), a hybrid E2-E3 ubiquitin ligase (Mashtalir et al., 2014; Vila et al., 2017; Zhang et al., 2013a), as being critical for Tat transcriptional activity. We show that Tat recruits UBE2O to robustly ubiquitinate HEXIM1 in a non-degradative manner. Interestingly, UBE2O-dependent ubiquitinated HEXIM1 species are largely cytoplasmic, which led to the discovery of a cytoplasmic pool of P-TEFb-7SK snRNP. Tat-dependent HEXIM1 ubiquitination by UBE2O releases P-TEFb from this cytoplasmic reservoir with the 7SK snRNP, resulting in the nuclear import of the active kinase. Our results reveal an unanticipated amount of cytoplasmic regulation of HIV-1 transcription, where the Tat protein co-opts ubiquitination machinery to reorganize a major transcription elongation complex. Further, UBE2O activity is essential for the Tat-dependent recruitment of P-TEFb to the viral promoter, demonstrating the importance of this ubiquitin ligase in targeting P-TEFb to chromatin. Finally, this mechanism of transcription elongation control appears to be more broadly used as treatment of cells with the CDK9 inhibitor, DRB, similarly resulted in P-TEFb nuclear import and chromatin retention with an increased association between UBE2O and HEXIM1.

Results

**UBE2O is a critical regulator of Tat transcriptional activity**

Our previous proteomic interaction study identified several high-confidence host binding partners for the HIV-1 Tat protein (Jäger et al., 2011b), including well-established and novel interactions. While the contributions of the P-TEFb-based super elongation complex (SEC) (He et al., 2010; Lin et al., 2010; Schulze-Gahmen et al., 2014; Sobhian et al., 2010) and 7SK snRNP (D’Orso and Frankel, 2010; Muniz et al., 2010) to regulating viral transcription has become better defined, the functions of additional Tat interactors are largely unexplored. Many of these Tat factors are involved in ubiquitin signaling, including PJA2, a ubiquitin ligase that directly modifies Tat to regulate transcription (Faust et al., 2017). In addition, Tat also interacts with the ubiquitin ligases ZFP91 and UBE2O. ZFP91 ubiquitinates NF-κB-inducing kinase via a Lys63 linkage to activate a non-canonical NF-κB pathway (Jin et al., 2010). UBE2O is a hybrid E2-E3 ubiquitin ligase that can ubiquitinate multiple chromatin-associated proteins within their nuclear localization signal (NLS), resulting in cytoplasmic retention (Mashtalir et al., 2014). UBE2O has also recently been shown to induce the degradation of the mixed-lineage leukemia (MLL) protein, which is commonly fused to members of the P-TEFb-based super elongation complex in leukemia (Liang et al., 2017).

To explore the activity of ZFP91 and UBE2O in HIV-1 transcription, we performed RNAi-mediated knockdowns of these ubiquitin ligases coupled to a functional assay for Tat activity. We used a HeLa cell line harboring a single, full-length HIV-1 provirus deleted for the tat gene (HeLa provirusΔtat).
(Faust et al., 2017), which allowed us to precisely control transcriptional activation by transfection of a Tat plasmid and to monitor Tat activity in a relatively natural proviral context by the production of intracellular HIV-1 capsid protein (p24). A small quantity of Tat plasmid (0.5 ng) was transfected within the linear range of the activation assay approximating physiological Tat concentrations, and loss-of-function effects for the ligases were assessed (Figure 1A).

Multiple independent siRNAs targeting ZFP91 or UBE2O inhibited Tat activity by 2-fold or greater, an effect similar to knockdown of the P-TEFb subunits CCNT1 and CDK9 (Figure 1A, Figure 1—figure supplement 1A, Figure 1—source data 1). Importantly, both ligases are expressed in CD4+ T cells (Figure 1—figure supplement 1B), underscoring that they can regulate Tat activity during normal viral infection of target immune cells. To determine whether ZFP91 and UBE2O specifically regulate transcription elongation, we measured promoter-proximal and -distal HIV-1 RNA production in the HeLa provirus tat cells and found that UBE2O knockdown significantly reduced the Tat-dependent production of distal, but not proximal, transcripts (Figure 1B, Figure 1—source data 2). These data strongly implicate UBE2O as an essential regulator of HIV-1 transcription elongation.

**UBE2O interacts with the HEXIM1 protein of the 7SK snRNP**

Since the 7SK snRNP complex is critical in regulating pause release at the HIV-1 promoter (D’Orso and Frankel, 2010), we affinity purified the HEXIM1 protein of the snRNP for mass spectrometry to better define the machinery involved in pause release and potentially make connections to the ubiquitin ligases. As expected, we observed interactions with P-TEFb and other components of the snRNP complex (Figure 1C). Intriguingly, UBE2O was identified as a HEXIM1 interactor from multiple purifications (Figure 1C, Supplementary file 1). The HEXIM1-UBE2O interaction was also identified in a recent effort to map the human interactome by systematic AP-MS of 2594 bait proteins (Huttlin et al., 2015), further validating the interaction. As additional support for the interaction of HEXIM1 and UBE2O, both proteins were identified in peak overlapping fractions from gel filtration of whole cell extracts (Figure 1D). As both HEXIM1 and Tat can bind UBE2O, we also examined how Tat expression might alter the HEXIM1-UBE2O interaction. Tat dramatically increased the association between endogenous HEXIM1 and transfected UBE2O (Figure 1E), supporting the ability of a viral transcription factor to induce the binding between a ubiquitin ligase and a major transcriptional regulatory protein. We next performed a tandem affinity purification of Tat-STREP and UBE2O-FLAG followed by western blotting of endogenous HEXIM1, which demonstrated that these three proteins can form a multi-protein complex (Figure 1F). Given these strong connections to HEXIM1 and because the 7SK snRNP plays a key role in activating viral transcription elongation, we decided to further investigate the activity of UBE2O in regulating Tat function.

**Tat uses a novel interaction surface to bind the 7SK snRNP and UBE2O**

Tat forms an extensive interaction surface on the CCNT1 subunit of P-TEFb (Tahirov et al., 2010). Given that Tat also potently recruits UBE2O to HEXIM1 (Figure 1E and F), we reasoned that Tat likely uses an additional binding surface to promote this interaction. To explore whether a novel functional interface might exist, we used a data set in which all Tat alanine point mutants were tested for activity in a transcriptional reporter system (D’Orso et al., 2012; Fernandes et al., 2016) and mapped the activities of these mutants onto the Tat–P-TEFb crystal structure (Tahirov et al., 2010). Several known regions in Tat were clearly defined where mutants displayed low transcriptional activity, including the cysteine-rich zinc-binding clusters (Figure 2A) and a stretch of hydrophobic residues (Phe38, Leu43, Gly44, and Ile45) buried in CCNT1 (Figure 2B). In support of a distinct interaction surface, a cluster of highly conserved, surface-exposed residues (Glu2, Tyr26, Lys28, and Phe32) displayed severe loss-of-function phenotypes and faced away from CCNT1 and CDK9 (Figure 2C).

To directly test if these residues constituted a new binding surface, we purified wild type and mutant Tat proteins from transiently transfected HEK 293 T cells and examined the interactions with endogenous proteins. Indeed, Tat K28A poorly bound to UBE2O and the 7SK snRNP proteins MEPCE and LARP7 (Figure 2D, Figure 2—figure supplement 1 for inputs). Of note, the interactions of these snRNP proteins with Tat is entirely RNA-dependent (Figure 2D, RNase A treatment), implicating Lys28 in 7SK snRNA binding in addition to its role in modulating the TAR RNA interaction.
Figure 1. UBE2O is a critical regulator of Tat-dependent transcription and binds HEXIM1 of the 7SK snRNP. (A) UBE2O and ZFP91 RNAi knockdown inhibit Tat-dependent transcription. Normalized, relative Tat activities ([p24^{host RNA}/FFL_1^{host RNA}]/[p24^{N.S. RNA}/FFL_1^{N.S. RNA}]) for CCNT1, CDK9, UBE2O, and ZFP91 are shown, and data are represented as the mean ± SEM of at least three biological replicates (defined as independent transfections. Cells were transfected independently on at least 2 different days) for independent siRNA transfections in the HeLa provirus tat cell line. (B) HIV RNA elongation Figure 1 continued on next page
Figure 1 continued

assay with ZFP91 (si2), UBE2O (si1), or CDK9 RNAi. Knockdowns were performed in the same cells as (A), which contain GFP cloned into the Nef locus. qPCR was used to monitor the Tat-dependent production of proximal (blue) and distal (red) RNA transcripts, with the relative positions of the primer sets shown above. Data are presented as the mean ± SEM of relative Tat activity of at least three biological replicates (same definition as above). (C) AP-MS results using HEXIM1-FLAG as the bait protein. Peptide counts are shown for selected prey proteins from triplicate biological purifications (as defined above). See also Supplementary file 1 for a complete list of interacting proteins. (D) Gel filtration of HEK 293T whole cell lysate. Fractions were collected after the void volume and Western blotted for the indicated proteins. ZFP91 is shown as a specificity control. (E) STREP purification of transfected proteins ± Tat co-transfection. The endogenous HEXIM1 interaction was monitored by western blot using an anti-HEXIM1 antibody. (F) Tandem affinity purification of Tat-STREP and UBE2O-FLAG from transfected cells. GFP-S-F (which is STREP and FLAG tagged) was used as a negative control in the experiment. The endogenous HEXIM1 interaction was detected by antibody. Different exposure times from the same blot for the HEXIM1 input and elutions are shown for ease of comparison. Schematic illustrates the Tat-HEXIM1-UBE2O complex.

DOI: https://doi.org/10.7554/eLife.31879.003

The following source data and figure supplement are available for figure 1:

Source data 1. Source data for luciferase-normalized p24 values of siRNA knockdown coupled to Tat activity of Figure 1A.
DOI: https://doi.org/10.7554/eLife.31879.004

Source data 2. Source data for proximal and distal Tat-dependent RNA species of Figure 1B.
DOI: https://doi.org/10.7554/eLife.31879.005

Figure supplement 1. RNAi-mediated protein knockdown and endogenous expression.
DOI: https://doi.org/10.7554/eLife.31879.006

[D’Orso and Frankel, 2009]. Strikingly, mutation of Phe32 (F32A), which is adjacent to Lys28 in the structure, significantly increased binding to UBE2O by greater than 4-fold. This might indicate that Phe32 is involved in a handoff from UBE2O to another protein, such that its mutation locks Tat in the UBE2O-bound state and completely inhibits transcriptional activity. Importantly, the P-TEFb interaction was unaffected by Lys28 or Phe32 mutations (Figure 2D), unlike the mutation of Phe38 (F38A) and Leu43 (L43A) residues that are buried in CCNT1 and disrupt P-TEFb binding, corroborating that Lys28 and Phe32 comprise a novel docking surface.

The SEC scaffold protein, AFF1, had an identical binding profile to CDK9 and CCNT1, supporting recent work that AFF1 is a ubiquitous P-TEFb binding partner (Lu et al., 2014). Transcriptional activity (D’Orso et al., 2012; Fernandes et al., 2016) and binding data both support a model in which Tat uses a buried hydrophobic patch (Phe38, Leu43) to anchor onto P-TEFb while using two spatially adjacent residues (Lys28, Phe32) to stabilize interactions with the 7SK snRNP and UBE2O (Figure 2E). Further, residues Lys28 and Phe32 were highly selected for during viral replication as assessed by deep mutational scanning, supporting a critical role of these amino acids (Fernandes et al., 2016). Thus, Tat encodes an essential hijacking function directed at a ubiquitin ligase and the 7SK snRNP.

Tat hijacks UBE2O to mono-ubiquitinate HEXIM1 in a non-degradative manner

Given that Tat induces the association of UBE2O and HEXIM1 (Figure 1E) and encodes a novel interaction surface for UBE2O and the 7SK snRNP (Figure 2D), we wanted to determine whether UBE2O ubiquitinates HEXIM1 and potentially other snRNP proteins, and how Tat might regulate this process. To test this, we first pulled down 7SK snRNP complex subunits and, upon blotting for transfected HA-tagged ubiquitin, found that UBE2O co-expression dramatically increased HEXIM1 and MEPCE ubiquitination but not LARP7, CCNT1, or CDK9 (Figure 3A). Correlating with the ubiquitination results, AP-MS experiments with the LARP7 and MEPCE subunits identified MEPCE, but not LARP7, as interacting with UBE2O (Figure 3—figure supplement 1A,B). As HEXIM1 is the key regulatory kinase inhibitor of the P-TEFb kinase (Michels et al., 2004) and is known to be ubiquitinated (Lau et al., 2009), we further characterized the HEXIM1 modification.

We first investigated the nature of the UBE2O-dependent ubiquitin linkage on HEXIM1, as recent work has shown that UBE2O monoubiquitinates numerous proteins (Mashtalir et al., 2014; Nguyen et al., 2017; Yanagitani et al., 2017; Zhang et al., 2013a). Similar to previous studies, expression of a lysine-free ubiquitin mutant (Ub ΔK), which blocks the ability to form polyubiquitin chains, did not affect UBE2O-dependent HEXIM1 ubiquitination in vivo (Figure 3B), demonstrating that HEXIM1 is monoubiquitinated at multiple sites. Further, a catalytically inactive mutant of UBE2O
Figure 2. Tat uses a novel interaction surface to interact with the 7SK snRNP and UBE2O. (A) Tat transcriptional activity data collected from our systematic set of alanine point mutants (D’Orso et al., 2012; Fernandes et al., 2016) was mapped onto the crystal structure of the Tat-P-TEFb complex (PDB i.d. 3MI9). The most severe loss-of-function (L.O.F.) mutations are shaded in deep purple while those with no effect on activity are shaded in white. The cysteine-rich zinc-binding clusters (A) and a hydrophobic stretch buried in CCNT1 (B) are critically important for Tat function. (C) A Figure 2 continued on next page
in the ubiquitin-conjugating domain (C1040S or CD) did not ubiquitinate HEXIM1 (Figure 3—figure supplement 2A), supporting specific modification by UBE2O. We next reconstituted ubiquitination of HEXIM1 by UBE2O in vitro and found that, like our observations in vivo, wild-type UBE2O but not the CD mutant robustly modified HEXIM1 (Figure 3C, Figure 3—figure supplement 2B). As also observed in vivo, multiple high-molecular-weight HEXIM1 species were generated using the Ub ΔK variant. Collectively, these results reveal that HEXIM1 is a UBE2O substrate that is monoubiquitinated at multiple sites.

Although targeting proteins for proteasomal destruction is a well-known function of ubiquitination, it is increasingly appreciated that this modification, especially mono-ubiquitination, also serves important signaling functions. Indeed, UBE2O-dependent ubiquitination of HEXIM1 was unaffected by treatment with the proteasome inhibitor MG132 (Figure 3D, Figure 3—figure supplement 2C showing MG132 control, Figure 3—figure supplement 2D showing extent of UBE2O overexpression), supporting a non-degradative mechanism. Strikingly, Tat expression increased HEXIM1 non-degradative mono-ubiquitination (Figure 3D), supporting a model of Tat-mediated HEXIM1 ubiquitination by UBE2O. Tat expression also increased the ubiquitination of endogenous HEXIM1, but not CCNT1 (Figure 3—figure supplement 3A), including a species with the same molecular weight as mono-ubiquitinated HEXIM1 (refer to Figure 3A). Importantly, Tat-stimulated non-degradative ubiquitination of endogenous HEXIM1 (Figure 3E) was completely blocked by siRNA-mediated knockdown of UBE2O (Figure 3E), signifying that Tat hijacks the enzyme for HEXIM1 mono-ubiquitination. In addition, UBE2O knockdown prevented endogenous, Tat-independent HEXIM1 ubiquitination, but did not increase HEXIM1 protein levels (Figure 3E), further confirming that HEXIM1 is an endogenous substrate for non-degradative UBE2O mono-ubiquitination, and is not an artifact of UBE2O overexpression. Importantly, HEXIM1 ubiquitination by UBE2O is a function that is exploited and induced by Tat (Figure 3E) to modulate viral transcription.

**UBE2O ubiquitinates the NLS of HEXIM1**

HEXIM1 ubiquitination resembles the modification of a recently described class of UBE2O substrates that are transcription factors with acceptor lysines contained within a bipartite NLS surrounding a patch of aliphatic hydrophobic amino acids (Mashtalir et al., 2014), termed the ‘VLI patch’, which is also found in UBE2O itself and results in auto-ubiquitination. This bipartite NLS motif is consistent with UBE2O’s preference for juxtaposed hydrophobic and basic patches (Yanagitani et al., 2017). Interestingly, while not identical, HEXIM1 has a similar motif (Figure 4A), with an NLS composed of 12 and 3 basic amino acid segments surrounding a stretch of mostly aromatic hydrophobic (W, Y) amino acids. To identify the sites of ubiquitination in HEXIM1 and to determine if the NLS is indeed a target, we first generated a fully lysine-free HEXIM1 mutant (ΔK) in which all lysines were mutated to arginine and observed no modification (Figure 4B, last lane), demonstrating that ubiquitination is lysine-dependent. When all lysines within the N- and C-termini were mutated to arginines (CTΔK + NTΔK), leaving lysines intact only within the NLS, HEXIM1 was still ubiquitinated.
Figure 3. HIV-1 Tat hijacks UBE2O for the non-degradative monoubiquitination of HEXIM1. (A) In vivo ubiquitination of transfected, STREP-tagged P-TEFb and 7SK snRNP proteins co-transfected with HA-ubiquitin ± co transfection of UBE2O-F or ZFP91-F (-F designates FLAG tagged protein). ZFP91 is used as a specificity control. Denaturing lysis and IPs were performed to detect ubiquitination by HA western blot. Ubiquitinated species are indicated. Schematics illustrate that UBE2O increases ubiquitination of the 7SK snRNP proteins MEPCE and HEXIM1. (B) In vivo ubiquitination of FAUST et al. eLife 2018;7:e31879. DOI: https://doi.org/10.7554/eLife.31879 Research article Biochemistry and Chemical Biology
HEXIM1-S in HEK 293 T cells co-transfected with UBE2O-F and either wild type or lysine-free (ΔK) HA-ubiquitin. Monoubiquitinated HEXIM1 and additional ubiquitinated species are indicated. (C) In vitro ubiquitination of HEXIM1 by UBE2O. HEXIM1-S purified from HEK 293T cells was incubated with recombinant E1 and ubiquitin, UBE2O-F purified from HEK 293T cells, and ATP. Control reactions lacked individual components as indicated. Additionally, one reaction was incubated with UBE2O CD (catalytically dead) purified from HEK 293T cells in place of wild type UBE2O (lane 6) or recombinant ubiquitin ΔK in place of wild type ubiquitin (lane 7). See also Figure 3—figure supplement 2C. (D) In vivo ubiquitination of HEXIM1-S co-transfected with UBE2O-F or Tat-F and subsequently treated with DMSO control or MG132 to block proteasomal degradation. See also Figure 3—figure supplement 2C. (E) HEK 293 T cells were transfected with non-silencing or UBE2O-directed siRNA (si1). Knockdown cells were then transfected with HIS-Ubiquitin L73P followed by a denaturing nickel purification. The L73P ubiquitin mutant was used to enrich for ubiquitinated species, which were detected by western blot using specific antibodies (anti-CDK9, anti-HEXIM1) on the nickel-purified elution and are indicated. Schematic illustrates that Tat enhances HEXIM1 ubiquitination through UBE2O.

DOI: https://doi.org/10.7554/eLife.31879.008

The following figure supplements are available for figure 3:

**Figure supplement 1.** FLAG-tagged MEPCE and LARP7 AP-MS.

DOI: https://doi.org/10.7554/eLife.31879.009

**Figure supplement 2.** A catalytically inactive UBE2O does not induce HEXIM1 ubiquitination.

DOI: https://doi.org/10.7554/eLife.31879.010

**Figure supplement 3.** Tat induces the ubiquitination of endogenous HEXIM1 and MEPCE.

DOI: https://doi.org/10.7554/eLife.31879.011

(Figure 4B), consistent with acceptor residues being located in the NLS. Several additional mutants suggest that lysines within the C-terminus can also be ubiquitinated (see Figure 4B legend), but we focused on the NLS modifications because of the previously defined connections to UBE2O (Mashtalir et al., 2014).

To more precisely map the acceptor sites, we used mass spectrometry (MS) and identified multiple ubiquitinated lysines in the NLS and C-terminus (Figure 4C, Supplementary file 2), supporting our initial mapping (Figure 4B). Since the HEXIM1 NLS is lysine and arginine-rich, not all peptides covering this region are detectable by MS after trypsin or Arg-C digestion. Therefore, as an alternative approach to map acceptor sites in the NLS, we restored individual lysines within the lysine-free (ΔK) background and found that four (Lys150, Lys151, Lys152, and Lys159) recovered monoubiquitination, with Lys151 and Lys159 being the most robust (Figure 4D). These four lysines are located within the first segment of the bipartite NLS, suggesting that they are the most accessible for UBE2O ubiquitination.

One intriguing possibility is that HEXIM1 is modified by UBE2O in the context of the 7SK snRNP, especially given the observation that Tat also stimulates HEXIM1 modification (Figure 3D,E) and is known to be in complex with the 7SK snRNP (D’Orso and Frankel, 2010; Jäger et al., 2011b; Muniz et al., 2010; Sobhian et al., 2010). Modification within the 7SK snRNP is also suggested by UBE2O binding and ubiquitination of MEPCE (Figure 3A, Figure 3—figure supplement 1A). In support of this model, a HEXIM1 mutant deficient for 7SK RNA binding (150–156 Ala) (Michels et al., 2004; Yik et al., 2004) displayed a complete loss of UBE2O-dependent ubiquitination, in striking contrast to another HEXIM1 mutant deficient for P-TEFb binding that was still fully ubiquitinated (202PYNT205 -> 202PDND205) (Michels et al., 2004) (Figure 4E). Because the 150–156 Ala mutant also lacks some of the lysines that become ubiquitinated (Figure 4D), we generated a HEXIM1 150–156 Arg mutant which similarly lacks the NLS acceptor lysines but retains RNA binding (Lau et al., 2009) and found that it was ubiquitinated equally to wild-type HEXIM1 (Figure 4E). Thus, RNA binding by HEXIM1 appears to be a prerequisite for UBE2O recognition and ubiquitination. 7SK RNA-binding releases HEXIM1 from an auto-inhibited state (Barboric et al., 2005), which likely establishes the proper conformation of HEXIM1 for UBE2O ubiquitination.

**UBE2O influences HEXIM1 subcellular localization**

Given that UBE2O ubiquitinates the NLS of HEXIM1, we next asked whether this modification resulted in a redistribution of HEXIM1 subcellular localization. Expression of UBE2O, itself a cytoplasmic ubiquitin ligase, altered the localization of endogenous HEXIM1 with an increase of HEXIM1 in the cytoplasm and a simultaneous decrease in the nuclear pellet fraction containing chromatin (Figure 5A). Consistent with the cytoplasmic accumulation of HEXIM1, the majority of the UBE2O-
**Figure 4.** UBE2O ubiquitinates the NLS of HEXIM1. (A) Domain organization of HEXIM1. The positions of the 23 lysines in HEXIM1 are indicated by yellow bars in the C-terminal (CT) and N-terminal (NT) regions and the NLS. (Below) Alignment of the NLS sequences from HEXIM1, UBE2O, and a known UBE2O substrate, BAP1 (Mashtalir et al., 2014). UBE2O and several of its target proteins contain a consensus bipartite NLS architecture that shares similarities with the HEXIM1 NLS. Basic residues are labeled in blue while hydrophobic residues are labeled in pink. (B) In vivo ubiquitination of HEXIM1 lysine mutants. Combinations of STREP-tagged lysine-to-arginine mutants were generated in the HEXIM1 N-terminal region (NTΔK), NLS Figure 4 continued on next page
(NLSΔK), and C-terminal region (CTΔK). A complete lysine-free HEXIM1 is designated as ΔK. UBE2O-F was co-transfected where indicated, and ubiquitination was detected by anti-HA western after denaturing lysis and IP. Monoubiquitin and multi-mono-ubiquitin species are indicated. The NTΔK mutant had no effect on ubiquitination, suggesting that there are no acceptor sites in the N-terminal region. However, both the NLSΔK and CTΔK mutants displayed decreased ubiquitination, demonstrating the presence of acceptor lysines in these regions. Schematic illustrates that lysines in the NLS (pink connection between domains) and in the C-terminal region function as acceptor sites. See also Supplementary file 2. (C) Coverage of the HEXIM1 sequence by MS. Sequences not identified by MS are bolded and underlined. Shaded in red is the HEXIM1 bipartite NLS. Color coding reflects whether a lysine was identified with a ubiquitin di-glycine tryptic remnant fragment. Shown below is a protein gel of HEXIM1-S purified under denaturing conditions from HEK 293 T cells with the co-expression of UBE2O-F. Arrows indicate unmodified and monoubiquitinated HEXIM1 species. The NTΔK mutant and all lysines are numbered in the HEXIM1 NLS and those that restore ubiquitination are indicated. (D) In vivo ubiquitination of individual lysine residues in the HEXIM1 NLS re-introduced in the context of the lysine-free (ΔK) HEXIM1 background. Ubiquitination of single-lysine HEXIM1 proteins was detected by HA Western blot. (top) All lysines are numbered in the HEXIM1 NLS and those that denote ubiquitination was detected by anti-HA western after denaturing lysis and IP. Monoubiquitin and multi-mono-ubiquitin species are indicated. (bottom) In vivo ubiquitination of wild-type STREP-tagged HEXIM1 or mutants deficient in binding P-TEFb (205PYNT205 -> 205PDND205) or the 7SK snRNA (150–156 Ala). HEXIM1-S was co-transfected with UBE2O-F as indicated. DOI: https://doi.org/10.7554/eLife.31879.012

dependent ubiquitinated species of HEXIM1 were also cytoplasmic (Figure 5B, lane 2), suggesting that HEXIM1 may be ubiquitinated in this fraction to regulate its localization and inhibit chromatin recruitment. It is also feasible that a nuclear fraction of UBE2O ubiquitinates nuclear HEXIM1, leading to its redistribution to the cytoplasm. This is particularly intriguing given UBE2O’s known nucleocytoplasmic shuttling activity and interactions with nuclear import/export machinery (Mashtalir et al., 2014). Interestingly, the lysine-free HEXIM1ΔK mutant, which is not ubiquitinated by UBE2O (Figure 4B), accumulated greater than threefold more in the chromatin-containing nuclear pellet compared to wild-type HEXIM1 when expressed in HEK 293 T cells (Figure 5C), further supporting a role of HEXIM1 lysine modification in regulating its localization. In this way, UBE2O likely acts to potentiate transcription by ubiquitinating HEXIM1 and promoting its sequestration in the cytoplasm, a mechanism co-opted by Tat during viral infection.

**HEXIM1 ubiquitination regulates interactions with the 7SK snRNP and is required for Tat-dependent P-TEFb release from the snRNP**

In addition to ubiquitinating the HEXIM1 NLS, UBE2O appeared to first require RNA binding by HEXIM1 for ubiquitination (Figure 4E). Given this requirement, we explored whether UBE2O ubiquitination might alter protein-protein interactions within a HEXIM1 RNP complex (Ray et al., 2014; Werner et al., 2015), in particular the 7SK snRNP or the recently described HEXIM1-NEAT1 RNP (Morchikh et al., 2017). Interestingly, the knockdown of UBE2O resulted in an increased association of CCNT1, CDK9, and LARP7 with endogenously purified HEXIM1 (Figure 6A), with no obvious effect on the HEXIM1 interactions with proteins of the NEAT1 RNP. This result supports the idea that UBE2O regulates HEXIM1 activity as part of the 7SK snRNP. Further, while Tat expression released HEXIM1 from the 7SK snRNP, with no effect on NEAT1 RNP interactions (Figure 6A), knockdown of UBE2O limited the ability of Tat to disrupt HEXIM1-CCNT1 binding. Together, these results underscore that UBE2O is involved in specifically regulating HEXIM1’s interaction with the 7SK snRNP in cells.

To further explore the role of UBE2O and Tat in altering HEXIM1’s interactions with the 7SK snRNP, we utilized the transcriptionally inactive Tat F32A variant, which has a mutant interaction phenotype that is specific to UBE2O (Figure 2D) and would allow us to uncover the role of this ligase in P-TEFb release from the 7SK snRNP. Unlike wild-type Tat, the F32A mutant was unable to stimulate HEXIM1 ubiquitination (Figure 6B) despite its increased association with UBE2O (Figure 2D), further supporting a non-productive binding mode of this Tat mutant to the ligase. Further, the F32A mutant was deficient in releasing P-TEFb from endogenous 7SK snRNP-bound HEXIM1 compared to wild type Tat (Figure 6C), corroborating a role for HEXIM1 ubiquitination in the P-TEFb eviction step by Tat. To further support the role of HEXIM1 ubiquitination in the release of P-TEFb, we utilized the HEXIM1 ΔK mutant, which is not ubiquitinated by UBE2O (Figure 4B). This lysine-free mutant was refractory to complete P-TEFb release by Tat (Figure 6D) compared to wild-type HEXIM1. Altogether, the data firmly support that HEXIM1 ubiquitination by UBE2O is a critical step in the eviction of P-TEFb from the 7SK snRNP by Tat.
Figure 5. UBE2O influences HEXIM1 subcellular localization. (A) Subcellular localization of endogenous HEXIM1. HEK 293T were transfected ±3 μg UBE20-F plasmid and fractionated into cytoplasmic (Cyto.), soluble nuclear (Nucl. sol.), and nuclear pellet (Nucl. pel.) fractions. Numbers represent quantified pixel intensity for HEXIM1 bands relative to un-transfected cells for the same fraction. Tubulin, SP1, and histone H4 were used as markers for each fraction and show the quality of the separations. HEXIM1 bands were first normalized to the pixel intensity of appropriate fraction controls (i.e. Figure 5 continued on next page).
Tat releases P-TEFb from cytoplasmic 7SK snRNP complexes for nuclear import and chromatin enrichment

Given the observation of HEXIM1 in the cytoplasm (Figure 5A,B) and the fact that UBE2O-dependent ubiquitination regulates HEXIM1’s interactions with the P-TEFb–7SK snRNP complex (Figure 6), we wished to determine if the full 7SK snRNP was contained in the cytoplasmic compartment. Indeed, a native IP of endogenous HEXIM1 from cytoplasmic and soluble nuclear fractions revealed robust RNA-dependent interactions between HEXIM1 and proteins of the P-TEFb-7SK snRNP complex in the cytoplasm (Figure 7A), agreeing with a previous finding that a significant fraction of a ‘large-form’ of P-TEFb is in the cytoplasm (Ramanathan et al., 1999). It should be noted that fractions were generated under salt concentrations that do not disassemble the 7SK snRNP (He et al., 2008). Immunofluorescence confirmed that a significant fraction of the CCNT1 subunit of P-TEFb was localized to the cytoplasm (Figure 7B), consistent with a previous observation that CCNT1 and CDK9 are detected in the cytoplasm in unstimulated resting memory CD4$^{+}$ T cells, the target immune cells of HIV-1 infection (Mbonye et al., 2013). Further, the interaction of HEXIM1 with 7SK snRNA was also detected in the cytoplasm (Figure 7C, Figure 7—source data 1). Altogether, the results establish that, in addition to the known nuclear pool of 7SK snRNP, a cytoplasmic reservoir of the full 7SK complex exists.

We next examined whether Tat utilizes this cytoplasmic pool of inhibited P-TEFb. Since newly translated Tat is cytoplasmic, especially during acute infection (Ranki et al., 1994; Kim et al., 2010), and shuttles between the nucleus and cytoplasm (Stauber and Pavlakis, 1998), we reasoned Tat might alter the localization of P-TEFb. Indeed, Tat expressed in HeLa cells, which we observed in cytoplasmic and nuclear fractions (Figure 7D, STREP western), decreased the amount of CCNT1 and CDK9 in the cytoplasm four-fold with a concomitant increase in the nuclear, chromatin-containing pellet (Figure 7D). Notably, localization of HEXIM1, of which nearly 30% is in complex with P-TEFb in HeLa cells (Barboric et al., 2007; Byers et al., 2005), was unaltered, supporting that free, and not snRNP-bound, P-TEFb enters the nucleus. P-TEFb nuclear import can be observed at the lowest Tat expression levels tested, arguing against an overexpression phenotype.

With the Tat-dependent increase of P-TEFb in the chromatin fraction (Figure 7D) and the involvement of UBE2O in Tat-dependent P-TEFb release (Figure 6), we examined whether UBE2O was involved in P-TEFb chromatin recruitment, specifically at the HIV-1 promoter. As expected, Tat expression increased the enrichment of CDK9 at the viral promoter (Figure 7E, Figure 7—source data 2). Importantly, knockdown of UBE2O greatly inhibited Tat-dependent CDK9 recruitment to the integrated viral promoter, supporting a critical role of this ligase in regulating viral transcription. UBE2O knockdown also prevented CDK9 enrichment in the absence of Tat, supporting an endogenous role of UBE2O in regulating HEXIM1 ubiquitination and maintaining appropriate P-TEFb kinase levels on the HIV-1 promoter.

The transcriptional inhibitor DRB re-localizes P-TEFb from the cytoplasm to the nucleus

Viruses often hijack existing host mechanisms; therefore, to investigate whether the nuclear import of P-TEFb freed from cytoplasmic 7SK snRNP might be a more general pathway to regulate transcriptional elongation, we used the CDK7/9 inhibitor 5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB), which blocks transcription elongation by decreasing RANAP II serine two phosphorylation (S2-P) (Koga et al., 2015). RANAP II S2-P levels dramatically decreased when HeLa cells were treated with DRB (Figure 8A). Remarkably, similar to Tat, DRB treatment induced extensive re-localization
Figure 6. HEXIM1 ubiquitination is required for Tat-dependent release of P-TEFb from the inhibitory 7SK snRNP complex. (A) Endogenous IP of HEXIM1 in non-silencing (n.s.) and UBE2O RNAi cells, ±Tat expression. Rabbit IgG was used as a negative IP control. Western blots were performed with the specific endogenous antibodies indicated to detect HEXIM1 protein-protein interactions. (B) In vivo ubiquitination assay of HEXIM-S. Wild type Tat or the F32A mutant was co-transfected as indicated. HEXIM1 ubiquitination was monitored by anti-HA western. The monoubiquitinated HEXIM1

Faust et al. eLife 2018;7:e31879. DOI: https://doi.org/10.7554/eLife.31879
of P-TEFb, but not HEXIM1, from the cytoplasm to the nuclear pellet, the same fraction containing reduced RNAP II S2-P. Supporting a role of UBE2O in this import pathway, DRB treatment also increased the association between UBE2O and endogenous HEXIM1 (Figure 8B). Given that DRB is a transcriptional inhibitor, one possibility is that P-TEFb nuclear import is part of a transcriptional stress response that senses and maintains proper polymerase phosphorylation in the nucleus. These results substantiate a model whereby re-localization of free P-TEFb to the nucleus is an important regulatory mechanism to sustain proper RNAP II S2-P levels.

Discussion

Since HIV-1 has a small 9-kilobase genome encoding only 18 proteins, it has evolved ways to economically utilize its limited genetic information and rely heavily on host protein complexes to execute all stages of its life cycle. Here we show that the viral transcription factor Tat hijacks a new host partner, UBE2O, which ubiquitinates transcription machinery to enhance viral transcription. UBE2O binds Tat via an interaction surface distinct from the well-known surface used to bind P-TEFb (Tahirov et al., 2010). We discovered that a single lysine (Lys28) and adjacent phenylalanine (Phe32) in Tat are largely responsible for the interaction with UBE2O. The requirement of just a few critical residues for interaction helps further explain how Tat can rewire large host complexes for its function using relatively little genetic information. Previous structural work has implicated Lys28 and Phe32 in directly binding AFF4 of the SEC (Schulze-Gahmen et al., 2014) and thus may be an interaction ‘hot spot’. Interestingly, while AFF4 is localized exclusively to the nucleus (Figure 7D), Tat recruits UBE2O to the 7SK snRNP in the cytoplasm and thus the ‘hot spot’ can be used to form complexes with different host partners in distinct cellular compartments.

A classic example of transcriptional regulation being coupled to signaling events in the cytoplasm is illustrated by the NF-κB pathway, where the application of a stimulus (e.g. TNFα) leads to the cytoplasmic degradation of inhibitor of κB (IκB) and subsequent nuclear import of NF-κB to activate gene expression (Napetschnig and Wu, 2013). By analogy, we find a significant pool of the inhibitory 7SK snRNP-P-TEFb complex in the cytoplasm, presumably reflecting the ‘large’ P-TEFb complexes previously described (Ramanathan et al., 1999), that serves as an inactive reservoir of P-TEFb. Surprisingly, Tat expression resulted in a significant redistribution of the P-TEFb subunits CCNT1 and CDK9, but not HEXIM1, from the cytoplasm to the histone-containing nuclear fraction, confirming that Tat can utilize this pool of inhibited P-TEFb. High FRET signal between Tat and CCNT1 in the cytoplasm (Marcello et al., 2001) and an intrinsic nucleocytoplasmic shuttling activity of CDK9 (Napolitano et al., 2002) support this hypothesis. Similar to NF-κB signaling, the P-TEFb nuclear import pathway also employs ubiquitination in that UBE2O-dependent modification of HEXIM1 is important for initial P-TEFb release from the 7SK snRNP (Figure 6). Intriguingly, UBE2O inhibits NF-κB activation by preventing the polyubiquitination of TRAF6 (Zhang et al., 2013b), suggesting that UBE2O is potentially intercalated in a signaling pathway that regulates stimulus-dependent NF-κB and P-TEFb nuclear import. An exciting future direction is to detail the additional cellular machinery that controls this multi-compartment signaling pathway.

We also demonstrated that another host protein, ZFP91, is important for Tat-dependent transcription (Figure 1A). ZFP91 is a classical C2H2 zinc finger (ZnF) protein, and while ZnF domains generally function as DNA-binding motifs, a previous report demonstrated that one ZFP91 ZnF domain can function as an atypical E3 ubiquitin ligase (Jin et al., 2010). We were unable to identify any substrate proteins for ZFP91 ligase activity in the Tat-P-TEFb transcriptional network. It will be interesting to determine whether ZFP91 mediates Tat co-activation through ubiquitination, and, if so, to identify the substrates of this activity. The previously identified target of ZFP91 ubiquitination was NF-κB-inducing kinase (NIK) (Jin et al., 2010), which is involved in activating the noncanonical NF-κB pathway. Therefore, in addition to the NF-κB binding sites in the HIV-1 promoter, Tat binds
Figure 7. Tat utilizes UBE2O for the chromatin recruitment of P-TEFb released from a cytoplasmic pool of 7SK snRNP. (A) Endogenous HEXIM1 IP using cytoplasmic and soluble nuclear fractions. One sample from each fraction was treated with RNAse A prior to the IP to evaluate RNA-dependence of interactions. (B) Immunofluorescence analysis of endogenous CCNT1 in HeLa tat provirus cells, demonstrating nuclear and cytoplasmic staining. Nuclei were stained with DAPI. (C) RNA-IP assay of the 7SK snRNA. An endogenous HEXIM1 IP was performed using cytoplasmic and soluble nuclear fractions.
two NF-κB regulatory proteins (ZFP91 and UBE2O), demonstrating that HIV-1 has heavily co-opted this host transcription pathway to control its own gene expression.

Many diverse stimuli are known to release P-TEFb from the 7SK snRNP (Amente et al., 2009; Bartholomeeusen et al., 2012; Biglione et al., 2007; Contreras et al., 2007; Nguyen et al., 2001), so nuclear import of the free kinase as described here is likely a general mechanism to control...
Figure 9. Model of basal and Tat-activated HIV-1 transcription. (Top) Basal transcription. The inhibited P-TEFb-7SK snRNP complex resides in the cytoplasm and bound to RNAP II at the viral promoter. Inhibition of P-TEFb kinase activity pauses the RNAP II-7SK snRNP complex at the promoter. UBE2O, also residing in the nucleus and cytoplasm, ubiquitinates HEXIM1, resulting in the sequestration of HEXIM1 in the cytoplasm and the nuclear import/retention of P-TEFb. This freed P-TEFb is then able to phosphorylate RNAP II, leading to low-level activation. (Bottom) Activated transcription. Figure 9 continued on next page
transcription elongation and not restricted to this viral case. Indeed, treatment of cells with the CDK inhibitor DRB potently relocalized P-TEFb to the nuclear pellet fraction, phenocopying the Tat effect (Figure 8A). As many compounds releasing P-TEFb from 7SK snRNP are inhibitors, particularly of transcription, nuclear import of the freed kinase might be part of a transcriptional stress response pathway. In this model, a likely signal of transcriptional stress is the phosphorylation state of RNAP II. Any decrease in RNAP II phosphorylation is then sensed and relayed to the cytoplasm, where P-TEFb is freed from the inhibitory snRNP. It will be interesting to define which cellular machinery sense the phosphorylation status of RNAP II, and how this signal is relayed to the cytoplasm to ultimately restore RNAP II phosphorylation.

The hijacking of the UBE2O E3 ligase by Tat results in ubiquitination of the HEXIM1 protein of the 7SK snRNP and adds a new dimension to viral transcriptional regulation. Monoubiquitination by UBE2O does not cause protein degradation but rather stimulates two signaling outcomes, adding to the growing list of functions for ubiquitination (Gatti et al., 2015; Thorslund et al., 2015; Werner et al., 2015; Yuan et al., 2014). First, ubiquitinated HEXIM1 displays decreased enrichment in the chromatin fraction and accumulates in the cytoplasm (Figure 5A,C), which is analogous to a previously reported function of UBE2O ligase activity in regulating the localization of chromatin-associated proteins by increasing their cytoplasmic retention (Mashtalir et al., 2014). Second, HEXIM1 ubiquitination is important for the Tat-dependent release of P-TEFb from the 7SK snRNP and recruitment to the viral promoter for transcription activation. These two signaling outcomes of UBE2O activity are coupled in that ubiquitination both aids P-TEFb nuclear import and sequesters HEXIM1 in the cytoplasm, which could sustain P-TEFb kinase activity in the nucleus by limiting reassociation of the free kinase with its inhibitor. Our findings reveal that the coordination of multiple localization pathways is involved in regulating transcription elongation.

The data presented here lead to an updated model of Tat activation (Figure 9). As shown previously (D’Orso and Frankel, 2010), the P-TEFb-7SK snRNP complex is recruited to the HIV-1 promoter in its basal state (without Tat), resulting in P-TEFb inhibition and accumulation of paused RNA polymerase II at the promoter, consequently poising the system for activation. In addition, UBE2O ubiquitinates nuclear and cytoplasmic HEXIM1, sequestering HEXIM1 in the cytoplasm and releasing some P-TEFb from the 7SK snRNP for nuclear import and retention. This activity of UBE2O supports basal, low-level HIV-1 gene expression.

Once Tat is expressed (Figure 9, bottom), it is also recruited to the HIV-1 promoter. The synthesis of TAR triggers Tat-dependent release of the 7SK snRNP, activating the P-TEFb kinase. Tat also binds UBE2O, further increasing HEXIM1 ubiquitination, thereby inducing P-TEFb release from the 7SK snRNP and promoting sequestration of HEXIM1 in the cytoplasm. Tat appears to target both the nuclear and cytoplasmic pools of the 7SK snRNP complex. P-TEFb that is released from the cytoplasmic pool enters the nucleus to sustain high-level transcriptional activation in Tat-expressing cells. The ability of Tat to hijack multiple reservoirs of P-TEFb helps explain its potent transcriptional activity. At the moment, it is unclear how Tat times the usage of the distinct fractions of P-TEFb–7SK snRNP. However, work presented here demonstrates that as Tat expression levels increase, more of the cytoplasmic P-TEFb reservoir is utilized, as evidenced by the dose response of Tat protein levels and the increase in P-TEFb nuclear import (Figure 7D). Given that DRB, a compound that induces stress and thus 7SK snRNP disassembly, also increases P-TEFb nuclear import and retention, it may be likely that the nuclear import of free P-TEFb kinase is a more general regulatory mechanism that is not restricted to HIV-1 transcription.

DOI: https://doi.org/10.7554/eLife.31879.019
## Materials and methods

### Key resources table

| Reagent type (species) or resource | Designation       | Source or reference | Identifiers       | Additional information                                                                 |
|-----------------------------------|-------------------|--------------------|-------------------|------------------------------------------------------------------------------------------|
| Recombinant DNA reagent           | UBE2O-FLAG (plasmid) | this paper         |                   | vector:pcDNA4/TO, insert: full-length Homo sapiens UBE2O                                  |
| Recombinant DNA reagent           | HEXIM1-STREP (plasmid) | this paper         |                   | vector:pcDNA4/TO, insert: full-length Homo sapiens HEXIM1                                 |
| Sequence-based reagent            | ZFP91 siRNA #1    | Qiagen             | S05109223         |                                                                                          |
| Sequence-based reagent            | ZFP91 siRNA #2    | Qiagen             | S05109230         |                                                                                          |
| Sequence-based reagent            | ZFP91 siRNA #3    | Qiagen             | S05150985         |                                                                                          |
| Sequence-based reagent            | UBE2O siRNA #1    | Qiagen             | S04153863         |                                                                                          |
| Sequence-based reagent            | UBE2O siRNA #2    | Dharmacon          | J-008979–05       |                                                                                          |
| Sequence-based reagent            | UBE2O siRNA #3    | Dharmacon          | J-008979–06       |                                                                                          |
| Sequence-based reagent            | CDK9 siRNA        | Qiagen             | S00605066         |                                                                                          |
| Sequence-based reagent            | CCNT1 siRNA       | Qiagen             | S02625707         |                                                                                          |
| Sequence-based reagent            | Non-silencing siRNA | Qiagen          | S03650318         |                                                                                          |
| Cell line (Homo sapiens)          | HeLa (provirus\tat) | PMID: 28345603     |                   |                                                                                          |
| Peptide, recombinant protein      | HA-ubiquitin      | this paper         |                   | purified from E. coli BL21                                                              |
| Peptide, recombinant protein      | HA-ΔK ubiquitin   | this paper         |                   | purified from E. coli BL21                                                              |
| Peptide, recombinant protein      | UBE2O             | this paper         |                   | purified from HEK 293 T cells with high salt                                            |
| Peptide, recombinant protein      | UBE2O, catalytically inactive | this paper     |                   | purified from HEK 293 T cells with high salt                                            |
| Peptide, recombinant protein      | HEXIM1            | this paper         |                   | purified from HEK 293 T cells with high salt                                            |
| Commercial assay or kit           | HiPerFect transfection reagent | Qiagen             |                   | used for transfecting siRNA                                                              |
| Commercial assay or kit           | PolyJet Transfection reagent | Signa Gen         |                   | used for transfecting DNA                                                                |
| Commercial assay or kit           | STREP-tactin superflo flow resin | IBA Lifesciences |                   |                                                                                          |
| Antibody                          | anti-HA           | Covance            | MMS-101P          | RRID: AB_2314672, 1:2000 dilution                                                      |
| Antibody                          | anti-HEXIM1       | Abcam              | ab25388           | RRID: AB_2233058, 1:2000 dilution, also used for IP                                     |
| Antibody                          | anti-CDK9         | Santa Cruz Biotechnology | sc-13130 | RRID: AB_627245, used for ChIP                                                           |
| Antibody                          | anti-IgG          | Millipore          | 12–371            | RRID: AB_145840, used for ChIP                                                           |
| Antibody                          | anti-IgG          | Santa Cruz Biotechnology | sc-2027 | RRID: AB_737197, For IP                                                                 |

Continued on next page
| Reagent type (species) or resource | Designation       | Source or reference     | Identifiers         | Additional information |
|-----------------------------------|-------------------|-------------------------|---------------------|------------------------|
| Antibody                         | anti-RNA polymerase II | Santa Cruz Biotechnology | sc-899x RRID: AB_632359 | 1:2000 |
| Antibody                         | anti-CCNT1        | Santa Cruz Biotechnology | sc-8127 RRID: AB_2073892 | 1:2000 |
| Antibody                         | anti-CCNT1        | Santa Cruz Biotechnology | sc-10750 RRID: AB_2073888 | 1:2000 |
| Antibody                         | anti-MEPCE        | Santa Cruz Biotechnology | sc-82542 RRID: AB_2266399 | 1:1000 |
| Antibody                         | anti-SP1          | Santa Cruz Biotechnology | sc-14027 RRID: AB_2171049 | 1:5000 |
| Antibody                         | anti-AFF1         | Bethyl                  | A302-344A RRID: AB_1850255 | 1:1000 |
| Antibody                         | anti-AFF4         | Bethyl                  | A302-538A RRID: AB_1998985 | 1:1000 |
| Antibody                         | anti-UBE2O        | Bethyl                  | A301-873A RRID: AB_1309799 | 1:1000 |
| Antibody                         | anti-Ku70         | Bethyl                  | A302-624A-T RRID: AB_10554672 | 1:1000 |
| Antibody                         | anti-SFPQ         | Bethyl                  | A301-322A-T RRID: AB_937995 | 1:1000 |
| Antibody                         | anti-LARP7        | Aviva                   | ARP40847_P050 RRID: AB_1294403 | 1:2000 |
| Antibody                         | anti-LARP7        | Santa Cruz Biotechnology | sc-515209 RRID: AB_2728652 | 1:2000 |
| Antibody                         | anti-HEXIM1       | Everest                 | EB06964 RRID: AB_2118260 | 1:5000 |
| Antibody                         | anti-CDK9         | Santa Cruz Biotechnology | sc-8338 RRID: AB_2260303 | 1:2000 |
| Antibody                         | anti-CDK9         | ProMab                  | 30212 RRID: AB_2728653 | 1:2000 |
| Antibody                         | anti-TUBULIN      | Sigma-Aldrich           | T6199 RRID: AB_477583 | 1:10,000 |
| Antibody                         | anti-FLAG         | Sigma-Aldrich           | F1804 RRID: AB_262044 | 1:5000 |
| Antibody                         | anti-RNA pol II phosphor-Ser2 | Abcam | ab5095 RRID: AB_304749 | 1:2000 |
| Antibody                         | anti-STREP-HRP    | Millipore               | 71591 RRID: AB_10806716 | 1:5000 |
| Antibody                         | anti-histone H4   | Active Motif            | 39269 RRID: AB_2636967 | 1:5000 |

**Cell culture, plasmids, and reagents**

HeLa<sub>provirus<sup>tat</sup></sub>, HeLa (RRID:CVCL_0030), and HEK 293T (RRID:CVCL_0063) cells were maintained in DMEM (10% FBS, 1% pen/strep) at 37°C with 5% CO<sub>2</sub> and discarded after 25–30 passages. HeLa and HEK 293 T cells were purchased from ATCC as authenticated cell lines. The HeLa<sub>provirus<sup>tat</sup></sub> cell line was generated from an early frozen stock of authenticated HeLa cells and was validated by Southern blot, which has been detailed previously (Faust et al., 2017). Symptoms for mycoplasma contamination were not observed, therefore no test for mycoplasma contamination was performed. ZFP91 and UBE2O were cloned into pcDNA4-TO (Thermo) with a C-terminal 3x-FLAG tag. ZFP91, UBE2O, CCNT1, CDK9, HEXIM1, LARP7, MEPCE, and HIV-1 HXB2 Tat were cloned into pcDNA4-TO with a C-terminal 2xSTREP tag. Human ubiquitin was cloned into pcDNA4-TO containing an N-terminal HA tag. All HEXIM1 and HIV-1 Tat point mutants were generated by standard quick-change mutagenesis. The HEXIM1 ΔK mutants were ordered as a gBlock gene fragment from IDT with restriction sites.
and cloned into appropriate vectors. DNA was transfected with PolyJet (Signa Gen) and siRNA was transfected with HiPerFect (Qiagen) or RNAi MAX (Thermo). All transfections were performed according to manufacturer’s protocol. MG132 was purchased from Selleckchem (S2619). DRB was purchased from Abcam (ab120939). 2x and 4x Laemmli buffer were purchased from BioRad. Human E1 protein was a kind gift from the laboratory of John Gross.

Antibodies
Normal rabbit IgG (sc-2027), RNA polymerase II (sc-899x), CCNT1 (sc-8127 and sc-10750), MEPCE (sc-82542), and SP1 (sc-14027) were purchased from Santa Cruz Biotechnology. AFF1 (A302-344A), AFF4 (A302-538A), UBE2O (A301-837A), Ku70 (A302-624A-T), and SFPQ (A301-322A-T) antibodies were purchased from Bethyl. The HA antibody (MMS-101P) was purchased from Covance. LARP7 antibodies were purchased from Aviva (APR0847_P050) and Santa Cruz (sc-51209). HEXIM1 antibodies were purchased from Abcam (ab25388) and Everest (EB06964). CDK9 antibodies were purchased from Santa Cruz (sc-8338 and sc13130) and ProMab (30212). The tubulin (T6199) and FLAG (F1804) antibodies were purchased from Sigma. The RNA pol II phosphor-Ser2 (ab5095) was purchased from Abcam. The STREP-HRP antibody (71591) and IgG (12-371) were purchased from Millipore. The histone H4 antibody (39269) was purchased from Active Motif.

RNAi knockdown of Tat host factors
HeLa\textsuperscript{provirus\textsuperscript{Tat}} cells were transfected with non-silencing or specific siRNAs (Qiagen) at 5–10 nM final concentrations using HiPerFect. After 48 hours, cells were transfected with 0.5 ng Tat-expressing plasmid and 1 ng CMV-firefly luciferase plasmid as a transfection control using PEI. After an additional 48 hr, cells were lysed in cell lysis buffer (5 mM Tris-HCl pH 8.0, 85 mM KCl, 0.5% IGEPAL CA-630). Cell-associated HIV-1 p24 production was detected by p24 ELISA. In parallel, 10 µL of lysate was used in a standard luciferase assay. All p24 values were normalized to firefly luciferase activity for each siRNA to generate a relative Tat activity score, defined as \[ \frac{\text{p24}_{\text{host RNAi}}}{\text{FFL}_{\text{host RNAi}}} \div \frac{\text{p24}_{\text{N.S. RNAi}}}{\text{FFL}_{\text{N.S. RNAi}}} \]. For analysis of protein knockdown, 2x Laemmli sample buffer was added to siRNA-treated cells and then loaded onto gels. Knockdowns were determined by western blot with the indicated antibodies. siRNAs:

- ZFP91 #1: CTGCGGGCACACTTATCTTCAA (Qiagen, SI05109223)
- ZFP91 #2: CAGCTCTTTAAGTGAGGGTTA (Qiagen, SI05109230)
- ZFP91 #3: CCGCCACTCCTATGCTAGAA (Qiagen, SI05150985)
- UBE2O #1: TCCCGGGACCATTCCATGGAA (Qiagen, SI04153863)
- UBE2O #2: GACUUUAGGUUCCGUACAA (Dharmacon, J-008979–05)
- UBE2O #3: GUUGUAGAGUUGAAAGUUA (Dharmacon, J-008979–06)
- CDK9: TAGGGACATGAAGGCTGCTAA (Qiagen, SI00605066)
- CCNT1: AGGGCTTTGAACACTAATTGA (Qiagen, SI02625707)
- Non-silencing (N.S.): Qiagen All-Star negative control (SI03650318)

Denaturing in vivo ubiquitination assay
HEK 293T or HeLa cells were transfected using PolyJet with 7 µg total DNA containing STREP-tagged bait protein and HA-Ubiquitin for denaturing STREP IPs or HIS-Ubiquitin for denaturing HIS IPs. After 30 hr, cells were lysed in an equal volume SDS Lysis Buffer (2% SDS, 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5 mM DTT) for denaturing STREP IPs or PBS + 6M guanidinium-HCl for denaturing HIS IPs and boiled for 10 min. Boiled lysates were sonicated on a Fisher Sonic Dismembrator Model 500 and centrifuged in a microfuge at full speed. Cleared lysates were incubated with Strep-tactin Superflow Agarose or HisPur nickel resin for 3 hr at room temperature. For STREP elution, the resin was washed with RIPA buffer and bound material was eluted with 1x STREP elution buffer (IBA-GmbH). For HIS elution, resin was washed with PBS + 0.2% Triton X-100 and bound material was eluted with PBS + 250 mM imidazole. Ubiquitination of immunoprecipitated material was detected by HA western blot for STREP IP or with endogenous antibodies for HIS IP. For RNAi-ubiquitination experiments, cells were first transfected with siRNA for 48 hr prior to DNA transfection. For MG132 treatment, cells that had been transfected with DNA for 24 hr were then incubated with 2.5 µM MG132 for an additional 16 hr before harvesting.
Cloning, expression, and purification of recombinant proteins

Human wild type and ΔK ubiquitin with an N-terminal HA tag were cloned into the pGEX6p-1 vector (GE Healthcare) and expressed as a fusion protein with an N-terminal GST tag. The fusion proteins were expressed in E. coli BL21 (DE3). The GST-fusion proteins were digested on column with PreScission protease. The released ubiquitin proteins were collected and further purified by Superdex 200 Increase (GE Healthcare).

In vitro ubiquitination assay

Assays were performed in a total volume of 30 μL with 0.1 μM recombinant human E1, 0.1 μM wild type UBE2O or catalytically inactive UBE2O (both wild-type UBE2O and UBE2O CD were purified from HEK 293 T cells with high salt), 5 μM HA-tagged ubiquitin (wild type or ΔK) and 0.2 μM HEXIM1 (purified from HEK 293 T cells) in reaction buffer containing 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 1 mM DTT, 5 mM MgCl₂, 4 mM ATP at 37°C with constant shaking for 2 hr. Samples were quenched with 4x Laemmli sample buffer (containing 2-Mercaptoethanol) before analysis by SDS-PAGE. Ubiquitination of HEXIM1 was verified by immunoblotting with anti-HEXIM1 antibody.

RNA elongation assay

HeLa<sub>provirus<sup>Δtat</sup></sub> cells were transfected with siRNAs to obtain 10 nM final concentration. After 48 hr of RNAi, cells were transfected with a Tat-expressing plasmid for an additional 10 hr. RNA was purified on Zymo Quick-RNA Mini Prep columns (R1054) according to the manufacturer’s protocol, DNase-treated with TURBO DNase (Thermo), and used in RT-PCR reactions with a primer immediately downstream of the HIV-1 TAR sequence to detect short RNA species and oligo dT to detect Tat-activated, poly-adenylated messages. RNA abundance was then quantified by qPCR, and HIV-1 RNA levels (short and long) were normalized to RPLP0 RNA levels (housekeeping gene). Values are reported as relative Tat activity, defined as [HIV-1 RNA<sub>host RNAi</sub>/RPLP0 RNA<sub>host RNAi</sub>] / [HIV-1 RNA<sub>N.S. RNAi</sub>/RPLP0 N.S. RNAi].

Affinity purification and western blot

HEK 293T or HeLa cells were transfected with 7 μg total DNA containing STREP-tagged or FLAG-tagged bait protein. After 40 hr, cells were collected, lysed in Lysis Buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM MgCl₂, 0.5% Triton X-100, 0.2% Na-deoxycholate, Roche protease inhibitor cocktail) and rocked for 30 min at 4°C. Lysate was cleared and incubated with Streptactin Superflow resin slurry (IBA-GmbH) or magnetic M2-FLAG resin slurry (Sigma) at 4°C. The resin was washed with WASH buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 2 mM MgCl₂, 0.5% Triton X-100) and eluted with 1x STREP elution buffer (IBA-GmbH) or FLAG elution buffer (200 μg/mL 3x FLAG peptide, diluted in WASH buffer), shaking at RT for 30 min. The eluate was mixed 1:1 with 2x Laemmli sample buffer, boiled, and loaded on a SDS-PAGE gel. Proteins were detected with specific antibodies.

RNA-IP

A fraction of the elution from a STREP IP was resuspended in RNA Lysis Buffer (Zymo). RNA was then processed with Zymo Quick-RNA Mini Prep kit as detailed above. Primers specific for the 7SK snRNA were used in RT-qPCR reactions (7SK F: 5'-GGATGTGAGGCGATCTGGC-3', 7SK R: 5'-AAAAGAAAGGCAGACTGCCAC-3')

High-salt IP

For high-salt purification of UBE2O WT and CD from HEK 293 T cells, the same lysis and IP was performed as above. For washing, beads were washed 4x in High Salt Wash Buffer (25 mM Tris-HCl pH 8.0, 0.1% Triton X-100, 2 mM MgCl₂, 1 M NaCl, 0.5 mM DTT) and 2x in IP Dilution Buffer (25 mM
Tris-HCl pH 8.0, 0.1% Triton X-100, 2 mM MgCl₂, 150 mM NaCl, 0.5 mM DTT) and eluted as described.

Tandem IP
2 × 15 cm plates of HEK 293 T cells were transfected per condition with either 5 μg of Tat-STREP and 5 μg UBE2O-FLAG or 5 μg of GFP-STREP-FLAG. The same lysis and IP was performed as above for the first STREP IP. The STREP elution was then incubated with FLAG-M2 resin overnight at 4°C. FLAG resin was wash 4x with FLAG wash buffer (50 mM Tris pH 8.0, 2 mM MgCl₂, 0.1% Triton X-100, 150 mM NaCl). Bound material was eluted with the same FLAG elution buffer as above.

Endogenous IP
HeLa or HEK 293 T cells were lysed in Lysis Buffer. Cleared cell lysates were incubated with control IgG or specific antibodies (1–10 μg) for 3 hr. Protein A Dynabeads slurry (Life Technologies) was washed and added to antibody-lysate mixture for an additional 3 hr. Dynabeads were then washed with WASH buffer. For elution, 50 μL of 2x Laemmlı Buffer (BioRad) was added to beads and incubated at 65°C for 15 min, with occasional mixing. After elution, 1.5 μL of BME was added to eluate, which was then processed by SDS-PAGE and Western blotting.

Endogenous RNA-IP
Immunocomplexes were eluted with 50 μL of RNA elution buffer (10 mM EDTA pH 8.0, 1% SDS, 50 mM Tris-HCl pH 8.0) for 15 min at 65°C. RNA was purified from the elution on Quick-RNA MiniPrep columns as detailed above. 4 μL of DNase-treated RNA was used in an RT reaction with primers specific for the 7SK snRNA and quantitated by qPCR.

Affinity purification-mass spectrometry
AP-MS experiments were performed as previously described (Jaeger et al., 2011a; 2011b). Slight modifications were as follows: HEK 293 T cells were transfected with 5–20 μg plasmid complexed with PolyJet Reagent. After 40 hr, cells were harvested and washed in PBS, and then resuspended in Lysis Buffer. Following incubation at 4°C for 30 min on a tube rotator, lysates were centrifuged for 20 min at 4°C. Cleared lysates and 2 μg of 1x FLAG peptide (Sigma) were added to 20 μL anti-FLAG M2 magnetic beads and rotated for 2 hr at 4°C. FLAG beads were sequentially washed 3x with Wash Buffer (0.05% NP-40, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA) and 1x with Wash Buffer without NP-40. Beads were incubated with Elution Buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.05% RapiGest SF Surfactant (Waters)) on a vortex mixer at room temperature for 30 min. Eluates (10 μL) were processed and analyzed by mass spectrometry as previously described (Davis et al., 2015; Mirrashidi et al., 2015).

Gel filtration
HEK 293 T cells were lysed in Lysis Buffer. Cell extracts were filtered through a 0.22 μm filter and loaded on a Superdex 200 Increase 10/300 GL (GE Healthcare) in 1x phosphate-buffered saline containing 1 mM DTT. The flow rate was 0.7 mL/min and 0.5 mL fractions were collected after the elution of the void volume. Each fraction was subjected to western blot analysis.

Identification of ubiquitinated HEXIM1 lysines by MS
HEK 293 T cells in 11 × 15 cm plates were transfected with 1 μg of HEXIM1-S, 5 μg of UBE2O-F, and 2 μg of HA-Ub (to 15 μg DNA total with pBluescript) by PolyJet. After 48 hr, a denaturing STREP IP was performed on the lysate. Sample eluate was digested with trypsin or Arg-C (according to manufacturer’s protocol) and analyzed by mass spectrometry as previously described (Kane et al., 2015) with slight modifications. Briefly, the raw data was matched to protein sequences by the MaxQuant algorithm (version 1.5.2.8) (Cox and Mann, 2008). Data were searched against a database containing SwissProt Human (downloaded 12/2014), and the APEX2 sequence, concatenated to a decoy database where each sequence was randomized in order to estimate the false discovery rate (FDR). The data were filtered to obtain a peptide, protein, and site-level false discovery rate of 0.01.
**Subcellular fractionation**

HEK 293T or HeLa cells were collected and the pelleted cell volume (PCV) was measured. For DRB treatment, cells were treated with DMSO control or 100 μM DRB for 1 hr prior to harvesting. Cells were washed in 3x PCV of Buffer A (10 mM Tris-HCl, pH 8.0, 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM DTT, Roche protease inhibitor cocktail), resuspended in 5x PCV Buffer A, and allowed to swell on ice. Triton X-100 was then added to the cells to achieve a final concentration of 0.5% and rocked for 1 min. The cellular material was passed through a 25G needle and spun at 1500 x g for 5 min. The supernatant was collected as the cytoplasmic fraction. The nuclei were resuspended in ¼ pelleted nuclear volume (PNV) of Buffer B (20 mM Tris-HCl, pH 8.0, 25% glycerol, 1.5 mM MgCl₂, 20 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, Roche protease inhibitors). ¼ PNV of Buffer C (Buffer B with 1.2 M KCl) was then added drop-wise to nuclei, which were then rocked for 30 min. The suspension was centrifuged and the supernatant was collected as the high salt nuclear extract (nucleoplasm). The nuclear pellet was then resuspended in RIPA buffer and sonicated. The sonicated lysate was spun at full speed and the supernatant was collected as the nuclear pellet. A Bradford assay (BioRad) was used to determine the protein concentration in each fraction. 10 μg of protein from each fraction was analyzed by SDS-PAGE and western blot.

**Immunofluorescence**

HeLa provirus Tat cells on coverslips were fixed in 4% formaldehyde for 20 min, quenched with 0.15 M glycine, and permeabilized with 0.1% Triton X-100 for 15 min. Permeabilized cells were blocked with blocking buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 2% BSA, 10% goat serum) for 1 hr, and then incubated with anti-CCNT1 antibody (sc-10750) at dilution of 1:100 for 1 hr. Cells were then washed with PBS and incubated with goat anti-rabbit IgG-Alexa Fluor 555 (1:1000) and 100 ng/μL DAPI in blocking buffer. Cover slips were washed in PBS and mounted on slides with ProLong Gold antifade mounting solution (Thermo). Confocal images were obtained with a spinning disk confocal microscope (Nikon Ti-E microscope equipped with Yokagawa CSU-22) by using the 561 and 405 nm excitation for Alexa Fluor 555 epifluorescence and 4,6-diamidino-2-phenylindole (DAPI), respectively.

**Chromatin immunoprecipitation (ChIP)-qPCR**

HeLa provirus Tat cells were transfected with either N.S. or UBE2O siRNA to obtain a 10 nM final concentration. After 48 hr, cells were transfected with a Tat-expressing plasmid (pcDNA4 TO-Tat:FLAG) for the +Tat condition and a mock expressing plasmid control (pcDNA4 TO:FLAG) for the –Tat condition for an additional 15 hr. 8.0 × 10⁶ cells per ChIP were grown on 10 cm plates and were cross-linked with 0.5% formaldehyde for 10 min followed by addition of 150 mM glycine for 5 min to quench the crosslinking reaction. Cells were harvested and lysed for 30 min at 4°C with rotation in Farnham lysis buffer (5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP-40, 1 mM PMSF, 1x EDTA-free protease inhibitor tablet (Roche)) at a concentration of 10⁷ cells/mL. Nuclei were collected and resuspended in cold Szak’s RIPA buffer (50 mM Tris-HCl pH 8.0, 1% NP-40, 150 mM NaCl, 0.5% Na-Deoxycholate, 0.1% SDS, 2.5 mM EDTA, 1 mM PMSF, 1x EDTA-free protease inhibitor tablet (Roche)) to a final concentration of 2.5 × 10⁷ nuclei/mL. Nuclei were sonicated for 60 cycles (30 s ON, 30 s OFF) on a waterbath sonicator (Diagenode) to obtain DNA fragment sizes between 150 and 500 bp. Sheared chromatin was pre-cleared with Protein G beads for 1 hr at 4°C. Protein G beads (100 μL of 10 mg/mL stock, Thermo Fisher) were conjugated with 10 μg of the following antibodies: CDK9 (Santa Cruz Biotechnology, sc13130) and IgG (Millipore, 12–371). Antibody bound beads were washed with 5% BSA +RIPA for 1 hr. Pre-cleared sheared chromatin (8 × 10⁶ nuclei) was added to the blocked antibody bound beads and incubated overnight. Washes, elutions, and de-crosslinking was performed as previously described (McNamara et al., 2016). Primers used for qPCR amplification of the HIV promoter (HIV (+141) Fwd: 5’-GCTTAAGCCTCAATAAAGCTTGCTTTGAG-3’, HIV (+141) Rev: 5’-GTCTCTGCGTGAGAGATCTCTCGTGGC-3’).

**Acknowledgements**

We thank Dr. JJ Miranda, Dr. John Gross, and members of the Frankel laboratory for critically reading the manuscript and Dr. Orly Laufman for technical assistance with the immunofluorescence. Research reported in this publication was supported by the National Institute of Allergy and...
Infectious Diseases of the NIH under award numbers R01AI114362 and Welch Foundation grant number I-1782 (to ID) and by the National Institute of General Medical Sciences of the NIH under number P50GM082250 (to NJK and ADF). CWB was supported by a pre-doctoral award from the National Science Foundation Graduate Research Fellowship under Grant No. 2016220513.

Additional information

Funding

| Funder                                      | Grant reference number | Author                  |
|---------------------------------------------|------------------------|-------------------------|
| National Institute of General Medical Sciences | P50GM082250            | Nevan J Krogan          |
|                                             |                        | Alan D Frankel          |
| National Institute of Allergy and Infectious Diseases | R01AI114362            | Iván D’Orso             |
| Welch Foundation                            | I-1782                 | Iván D’Orso             |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

Tyler B Faust, Conceptualization, Investigation, Visualization, Writing—original draft, Writing—review and editing; Yang Li, Conceptualization, Investigation, Visualization, Writing—review and editing; Curtis W Bacon, Bhargavi Jayaraman, Investigation, Visualization, Writing—review and editing; Gwendolyn M Jang, Conceptualization, Investigation, Writing—review and editing; Amit Weiss, Billy W Newton, Investigation, Visualization; Nevan J Krogan, Supervision, Funding acquisition, Visualization, Writing—review and editing; Iván D’Orso, Visualization, Writing—review and editing; Alan D Frankel, Conceptualization, Resources, Supervision, Funding acquisition, Visualization, Writing—original draft, Project administration, Writing—review and editing

Author ORCIDs

Yang Li [i] https://orcid.org/0000-0003-0216-0350
Curtis W Bacon [i] https://orcid.org/0000-0001-6454-5470
Iván D’Orso [i] http://orcid.org/0000-0002-1409-2351
Alan D Frankel [i] http://orcid.org/0000-0002-2525-9508

Decision letter and Author response

Decision letter https://doi.org/10.7554/eLife.31879.026
Author response https://doi.org/10.7554/eLife.31879.027

Additional files

Supplementary files

- Supplementary file 1. Full HEXIM1, MEPCE, and LARP7 AP-MS lists. Each tab is a biological replicate FLAG affinity purification for the indicated protein.
  DOI: https://doi.org/10.7554/eLife.31879.020

- Supplementary file 2. HEXIM1-Ub diGly data, related to Figure 4. Tabs show raw data for all detected unmodified and modified HEXIM1 peptides (HEXIM1 tab) or the sum of MS/MS counts for peptides generated from trypsin or Arg-C treatment (HEXIM1 summ. tab).
  DOI: https://doi.org/10.7554/eLife.31879.021

- Transparent reporting form
  DOI: https://doi.org/10.7554/eLife.31879.022

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.
References

Amente S, Gargano B, Napolitano G, Lania L, Majello B. 2009. Camptothecin releases P-TEFb from the inactive 7sk snRNP complex. Cell Cycle 8:1249–1255. DOI: https://doi.org/10.4161/cc.8.8.2826
Barboric M, Kohoutek J, Price JP, Blazek D, Price DH, Peterlin BM. 2005. Interplay between 7SK snRNA and oppositely charged regions in HEXIM1 direct the inhibition of P-TEFb. The EMBO Journal 24:4291–4303. DOI: https://doi.org/10.1038/sj.emboj.7600883, PMID: 16362050
Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. 2001. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Molecular Cell 8:327–337. DOI: https://doi.org/10.1016/S1097-2765(01)00314-8, PMID: 11545735
Barboric M, Yik JH, Czudnochowski N, Yang Z, Chen R, Contreras X, Geyer M, Matija Peterlin B, Zhou Q. 2007. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Research 35:2003–2012. DOI: https://doi.org/10.1093/nar/gkm063, PMID: 17341462
Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. 2012. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. Journal of Biological Chemistry 287:36609–36616. DOI: https://doi.org/10.1074/jbc.M112.410746, PMID: 22952229
Biglione S, Byers SA, Price JP, Nguyen VT, Bensaude O, Price DH, Maury W. 2007. Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex. Retrovirology 4:47. DOI: https://doi.org/10.1186/1742-4690-4-47, PMID: 17625008
Byers SA, Price JP, Cooper JJ, Li Q, Price DH. 2005. HEXIM2, a HEXIM1-related protein, regulates positive transcription elongation factor b through association with 7SK. Journal of Biological Chemistry 280:16360–16367. DOI: https://doi.org/10.1074/jbc.M500424200, PMID: 15716662
Chen R, Liu M, Li H, Xue Y, Ramey WN, He N, Ai N, Luo H, Zhu Y, Zhou Z, Zhou Q. 2008. PP2B and PP1alpha cooperatively disrupt 7SK snRNP to release P-TEFb for transcription in response to Ca2+ signaling. Genes & Development 22:1356–1368. DOI: https://doi.org/10.1101/gad.1636008, PMID: 18483222
Contreras X, Barboric M, Lenasi T, Peterlin BM. 2007. HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription. PLoS Pathogens 3:e146–1469. DOI: https://doi.org/10.1371/journal.ppat.0030146, PMID: 17937499
Core LJ, Waterfall JJ, Lis JT. 2008. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322:1845–1848. DOI: https://doi.org/10.1126/science.1162228, PMID: 19056941
Cox J, Mann M. 2008. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nature Biotechnology 26:1367–1372. DOI: https://doi.org/10.1038/ntbio1511, PMID: 19029910
Czudnochowski N, Bosken CA, Geyer M. 2012. Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition. Nature Communications 3:842. DOI: https://doi.org/10.1038/ncomms1846, PMID: 22588304
D’Orso I, Frankel AD. 2009. Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex. PNAS 106:3101–3106. DOI: https://doi.org/10.1073/pnas.0900012106, PMID: 19223581
D’Orso I, Frankel AD. 2010. RNA-mediated displacement of an inhibitory snRNP complex activates transcription elongation. Nature Structural & Molecular Biology 17:815–821. DOI: https://doi.org/10.1038/nsmb.1827, PMID: 20562857
D’Orso I, Jang GM, Pastuszak AW, Faust TB, Quezada E, Booth DS, Frankel AD. 2012. Transition step during assembly of HIV Tat:P-TEFb transcription complexes and transfer to TAR RNA. Molecular and Cellular Biology 32:4780–4793. DOI: https://doi.org/10.1128/MCB.00206-12, PMID: 23007159
Davis ZH, Verschueren E, Jang GM, Kleffman K, Johnson JR, Park J, Von Dollen J, Maher MC, Johnson T, Newton W, Jäger S, Shales M, Hernandez RD, Krogan NJ, Glaunsinger BA. 2015. Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes. Molecular Cell 57:349–360. DOI: https://doi.org/10.1016/j.molcel.2014.11.031, PMID: 25544563
Eberhardt SR, Farnham PJ. 2002. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. Journal of Biological Chemistry 277:40156–40162. DOI: https://doi.org/10.1074/jbc.M207441200, PMID: 12177005
Faust TB, Li Y, Jang GM, Johnson JR, Yang S, Weiss A, Krogan NJ, Frankel AD. 2017. PJA2 ubiquitinates the HIV-1 tat protein with atypical chain linkages to activate viral transcription. Scientific Reports 7:45394. DOI: https://doi.org/10.1038/srep45394, PMID: 28345603
Feinberg MB, Baltimore D, Frankel AD. 1991. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. PNAS 88:4045–4049. DOI: https://doi.org/10.1073/pnas.88.9.4045, PMID: 2023953
Fernandes JD, Faust TB, Strauli NB, Smith C, Crosby DC, Nakamura RL, Hernandez RD, Frankel AD. 2016. Functional segregation of overlapping genes in HIV. Cell 167:1762–1773. DOI: https://doi.org/10.1016/j.cell.2016.11.031, PMID: 27984726
Gatti M, Pinato S, Maiolica A, Rocchio F, Prato MG, Aebersold R, Penengo L. 2015. RNF168 promotes noncanonical K27 ubiquitination to signal DNA damage. Cell Reports 10:226–238. DOI: https://doi.org/10.1016/j.celrep.2014.12.021, PMID: 25578731
Hammond-Martel I, Yu H, Affar ELB. 2012. Roles of ubiquitin signaling in transcription regulation. *Cellular Signalling* **24**:410–421. DOI: https://doi.org/10.1016/j.cellsig.2010.11.009, PMID: 20233037

Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. *Nature* **387**:296–299. DOI: https://doi.org/10.1038/387296a0, PMID: 9153995

He N, Jahchan NS, Hong E, Li Q, Bayfield MA, Maria RJ, Luo K, Zhou Q. 2008. A Lα-related protein modulates 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. *Molecular Cell* **39**:588–599. DOI: http://dx.doi.org/10.1016/j.molcel.2008.01.003, PMID: 18249148

He N, Liu M, Hsu J, Xue Y, Chou S, Burlingame A, Krogan NJ, Alber T, Zhou Q. 2010. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. *Molecular Cell* **38**:428–438. DOI: https://doi.org/10.1016/j.molcel.2010.04.013, PMID: 20471948

Henriques T, Gilchrist DA, Nechaev S, Bern M, Muse GW, BurkhOLDER A, Fargo DC, Adelman K. 2013. Stable pausing by RNA polymerase II provides an opportunity to target and integrate regulatory signals. *Molecular Cell* **52**:517–528. DOI: https://doi.org/10.1016/j.molcel.2013.10.010, PMID: 24184211

Huttlin EL, Ting L, Bruckner RJ, Gebreab F, Gygi MP, Szpyt J, Tam S, Zarraga G, Colby L, Baltier K, Dong R, Guaraní V, Vaites LP, Ordureau A, Rad R, Erickson BK, Wühr M, Chick J, Zhai B, Kolippakam D, et al. 2015. The BioPlex network: a systematic exploration of the human interactome. *Cell* **162**:425–440. DOI: https://doi.org/10.1016/j.cell.2015.06.043, PMID: 26186194

Jäger S, Cimermancic P, Gulbahce N, Johnson JR, McGovern KE, Clarke SC, Shales M, Mercenne G, Pache L, Li K, Hernandez H, Jang GM, Roth SL, Alkiva E, Marlett J, Stephens M, D’Orso I, Fernandes J, Fahey M, Mahon C, et al. 2011b. Global landscape of HIV-human protein complexes. *Nature* **481**:365–370. DOI: https://doi.org/10.1038/110719, PMID: 22190034

Jäger S, Gulbahce N, Cimermancic P, Kane J, He N, Chou S, D’Orso I, Fernandes J, Jang G, Frankel AD, Alber T, Zhou Q, Krogan NJ. 2011a. Purification and characterization of UFM1-dependent degradation pathways in MLL-Rearranged leukemia. *Molecular Cell* **30539–30547. DOI: https://doi.org/10.1016/j.molcel.2010.04.028

Kane JR, Hernandez H, Jang GM, Roth SL, Alkiva E, Marlett J, Stephens M, D’Orso I, Fernandes J, Fahey M, Mahon C, et al. 2011a. Purification and characterization of HIV-human protein complexes. *Nature* **481**:365–370. DOI: https://doi.org/10.1038/110719, PMID: 22190034

Kane JR, D’Orso I, Fernandes J, Jang G, Frankel AD, Alber T, Zhou Q, Krogan NJ. 2011a. Purification and characterization of HIV-human protein complexes. *Methods* **53**:13–19. DOI: https://doi.org/10.1016/j.ymeth.2010.08.007, PMID: 20708689

Ja¨ger S, Kane JR, Hernandez H, Jang GM, Roth SL, Alkiva E, Marlett J, Stephens M, D’Orso I, Fernandes J, Fahey M, Mahon C, et al. 2011b. Global landscape of HIV-human protein complexes. *Nature* **481**:365–370. DOI: https://doi.org/10.1038/110719, PMID: 22190034

Kra¨mer G, A¨ rna¨sfors J, Ki¨lipaloka¨ & Al¨a¨ila¨ J, 2015. Lineage-specific viral hijacking of non-canonical E3 ubiquitin ligase activity. *Molecular Cell* **52**:517–528. DOI: https://doi.org/10.1016/j.molcel.2013.10.010, PMID: 24184211

Jin X, Zhou Y, Pandit S, Huang J, Li H, Lin CY, Xiao R, Burge CB, Fu XD. 2013. SR proteins collaborate with 7SK snRNP integrity to suppress P-TEFb-dependent transcriptional elongation and tumorigenesis. *Molecular Cell* **52**:517–528. DOI: https://doi.org/10.1016/j.molcel.2013.10.010, PMID: 24184211

Kim N, Kukkonen S, Gupta S, Aldovini A. 2010. Association of Tat with promoters of PTEN and PP2A subunits is key to transcriptional activation of apoptotic pathways in HIV-infected CD4+ T cells. *PloS Pathogens* **6**

Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. 2003. Skp2 regulates Myc protein stability and activity. *Molecular Cell* **11**:1177–1188. DOI: https://doi.org/10.1016/S1097-2765(03)0173-4, PMID: 12796843

Koga M, Hayashi M, Kaida D. 2015. Splicing inhibition decreases phosphorylation level of Ser2 in Pol II CTD. *Nucleic Acids Research* **43**:8258–8267. DOI: https://doi.org/10.1093/nar/gkv740, PMID: 26202968

Kwak H, Fuda NJ, Core LJ, Lis JT. 2013. Precise maps of RNA polymerase reveal how promoters direct initiation and pausing. *Science* **339**:950–953. DOI: https://doi.org/10.1126/science.1229386, PMID: 23430654

Kwak H, Lis JT. 2013. Control of transcriptional elongation. *Annual Review of Genetics* **47**:483–508. DOI: https://doi.org/10.1146/annurev-genet-110711-155440, PMID: 24050178

Kwee, Liew, Kleijnen, van der Plas, and van der Greef. 2015. Analysis of gene expression in human blood cells. *Molecular Cell* **53**:13–26. DOI: https://doi.org/10.1016/j.molcel.2015.04.038, PMID: 25981045

Kunimoto KF, Kuroda M, Fujinaga K, Bartholomeeusen K, Nilson KA, Price DH, Peterlin BM. 2014. Release of positive elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates transcription elongation factor b (P-TEFb) from 7SK snRNP and formation of SECs for HIV transactivation. *PNAS* **111**

Faust et al. eLife 2018;7:e31879. DOI: https://doi.org/10.7554/eLife.31879 28 of 30
Marcello A, Cinelli RA, Ferrari A, Signorelli A, Tyagi M, Pellegrini V, Beltram F, Giacca M. 2001. Visualization of in vivo direct interaction between HIV-1 TAT and human cyclin T1 in specific subcellular compartments by fluorescence resonance energy transfer. *Journal of Biological Chemistry* **276**:39220–39225. DOI: https://doi.org/10.1074/jbc.M104830200, PMID: 11504720

Marshall NF, Price DH. 1995. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. *Journal of Biological Chemistry* **270**:12335–12338. DOI: https://doi.org/10.1074/jbc.270.21.12335, PMID: 7759473

Mashalir N, Daou S, Barbour H, Sen NN, Gagnon J, Hammond-Martel I, Dar HH, Therrien M, Affar EL. 2018. Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. *Molecular Cell* **54**:392–406. DOI: https://doi.org/10.1016/j.molcel.2014.03.002, PMID: 24703950

Mbonye OR, Gokulrangan G, Datt M, Dobrowolski C, Cooper M, Chance MR, Karn J. 2013. Phosphorylation of CDK9 at Ser175 enhances HIV transcription and is a marker of activated P-TEFb in CD4(+) T lymphocytes. *PLoS Pathogens* **9**:e1003338. DOI: https://doi.org/10.1371/journal.ppat.1003338, PMID: 23658523

McNamara RP, Reeder JE, McMillan EA, Bacon CW, McCann JL, D’Orso I. 2016. KAP1 recruitment of the 7sk snRNP complex topromoters enables transcription elongation by RNA polymerase II. *Molecular Cell* **61**:39–53. DOI: https://doi.org/10.1016/j.molcel.2015.11.004, PMID: 26725010

Michels AA, Fraldi A, Li Q, Adamson TE, Bonnet F, Nguyen VT, Sedore SC, Price JP, Price DH, Lania L, Besnade O. 2004. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. The EMBO Journal **23**:2608–2619. DOI: https://doi.org/10.1038/sj.emboj.7600275, PMID: 15201869

Mirareshidi KM, Elwell CA, Verschure E, Johnson FR, Frando A, Von Derollen B, Rosenberg O, Gulbahce N, Jang G, Johnson T, Jäger S, Gopalakrishnan AM, Sherry J, Dunn JD, Olive A, Penn B, Shales M, Cox JS, Starnbach MN, Derre I, et al. 2015. Global mapping of the Inc-Human interactome reveals that retromer restricts Chlamydia infection. *Cell Host & Microbe* **18**:109–121. DOI: https://doi.org/10.1016/j.chom.2015.06.004, PMID: 26118995

Morchik M, Cribier A, Raffel R, Amraoui S, Cau J, Severac D, Dubois E, Schwartz O, Bennasser Y, Benkirane M. 2017. HEXIM1 and NEAT1 long Non-coding RNA form a Multi-subunit complex that regulates DNA-Mediated innate immune response. *Molecular Cell* **67**:387–399. DOI: https://doi.org/10.1016/j.molcel.2017.06.020, PMID: 28712728

Muniz L, Egloff S, Ugly B, Jäde BY, Kiss T. 2010. Controlling cellular P-TEFb activity by the HIV-1 transcriptional transactivator Tat. *PLoS Pathogens* **6**:e1001152. DOI: https://doi.org/10.1371/journal.ppat.1001152, PMID: 20976203

Napetschnig J, Wu H. 2013. Molecular basis of NF-κB signaling. *Annual Review of Biophysics* **42**:443–468. DOI: https://doi.org/10.1146/annurev-biophys-083012-130338, PMID: 23495970

Napolitano G, Liai S, Carbone R, Majello B, Lania L. 2002. CDK9 has the intrinsic property to shuttle between nucleus and cytoplasm, and enhanced expression of cyclin T1 promotes its nuclear localization. *Journal of Cellular Physiology* **192**:209–215. DOI: https://doi.org/10.1002/jcp.10130, PMID: 12115727

Nguyen AT, Prado MA, Schmidt PJ, Sendamarai AK, Wilson-Grady JT, Min M, Campagna DR, Tian G, Shi Y, Dederer V, Kawan M, Kuehnle N, Paulo JA, Yao Y, Weiss MJ, Justice MJ, Gygi SP, Fleming MD, Finley D. 2017. HEXIM1 and NEAT1 long Non-coding RNA form a Multi-subunit complex that regulates DNA-Mediated innate immune response. *Molecular Cell* **67**:387–399. DOI: https://doi.org/10.1016/j.molcel.2017.06.020, PMID: 28712728

Rahl PB, Lin CY, Seila AC, Flynn RA, McQuine S, Burge CB, Sharp PA, Young RA. 2010. c-Myc regulates transcriptional pause release. *Cell* **141**:432–445. DOI: https://doi.org/10.1016/j.cell.2010.03.030, PMID: 20434984

Ramanathan Y, Reza SM, Young TM, Mathews MB, Pe’ery T. 1999. Human and rodent transcription elongation factor P-TEFb: interactions with human immunodeficiency virus type 1 tat and carboxy-terminal domain substrate. *Journal of Virology* **73**:5484–5485. PMID: 10364292

Ranki A, Lagerstedt A, Ovod V, Avvik E, Krohn KJ. 1994. Expression kinetics and subcellular localization of HIV-1 regulatory proteins nef, tat and rev in acutely and chronically infected lymphoid cell lines. *Archives of Virology* **139**:365–378. DOI: https://doi.org/10.1007/BF01310798, PMID: 7832642

Ray S, Zhao Y, Jamaluddin M, Edeh CB, Lee C, Brasier AR. 2014. Inducible STAT3 NH2 terminal monoubiquitination promotes BRD4 complex formation to regulate apoptosis. *Cellular Signalling* **26**:1445–1455. DOI: https://doi.org/10.1016/j.cellsig.2014.03.007, PMID: 24657799

Schulze-Gahmen U, Lu H, Zhou Q, Alber T. 2014. AFF4 binding to Tat-P-TEFb indirectly stimulates TAR recognition of super elongation complexes at the HIV promoter. *eLife* **3**:e02375. DOI: https://doi.org/10.7554/eLife.02375, PMID: 24843025

Sobhian B, Laguette N, Yatim A, Nakamura M, Levy K, Kiernan R, Benkirane M. 2010. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. *Molecular Cell* **38**:439–451. DOI: https://doi.org/10.1016/j.molcel.2010.04.012, PMID: 20471949

Stauber RH, Pavlakis GN. 1998. Intracellular trafficking and interactions of the HIV-1 tat protein. *Virology* **252**:126–136. DOI: https://doi.org/10.1006/viro.1998.9400, PMID: 9875323

Faust et al. *eLife* 2018;7:e31879. DOI: https://doi.org/10.7554/eLife.31879
Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH. 2010. Crystal structure of HIV-1 Tat complexed with human P-TEFb. *Nature* 465:747–751. DOI: https://doi.org/10.1038/nature09131, PMID: 20535204

Takahashi H, Parmely TJ, Sato S, Tomomori-Sato C, Banks CA, Kong SE, Szutorisz H, Swanson SK, Martin-Brown S, Washburn MP, Florens L, Seidel CW, Lin C, Smith ER, Shilatifard A, Conaway RC, Conaway JW. 2011. Human mediator subunit MED26 functions as a docking site for transcription elongation factors. *Cell* 146:92–104. DOI: https://doi.org/10.1016/j.cell.2011.06.005, PMID: 21729782

Thorslund T, Rippolinger A, Hoffmann S, Wild T, Uckelmann M, Villumsen B, Narita T, Sixma TK, Choudhary C, Bekker-Jensen S, Mailand N. 2015. Histone H1 couples initiation and amplification of ubiquitin signalling after DNA damage. *Nature* 527:389–393. DOI: https://doi.org/10.1038/nature15401, PMID: 26503038

Vila IK, Yao Y, Kim G, Xia W, Kim H, Kim SJ, Park MK, Hwang JP, González-Billalabeitia E, Hung MC, Song SJ, Song MS. 2017. A UBE2O-AMPKα2 Axis that promotes tumor initiation and progression offers opportunities for therapy. *Cancer Cell* 31:451–462. DOI: https://doi.org/10.1016/j.ccell.2017.01.003, PMID: 28162974

Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. 1998. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. *Cell* 92:451–462. DOI: https://doi.org/10.1016/S0092-8674(00)80939-3, PMID: 9491887

Werner A, Iwasaki S, McGourty CA, Medina-Ruiz S, Teerikorpi N, Fedrigo I, Ingolia NT, Rape M. 2015. Cell-fate determination by ubiquitin-dependent regulation of translation. *Nature* 525:523–527. DOI: https://doi.org/10.1038/nature14978, PMID: 26399832

Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J, Handa H. 1999. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. *Cell* 97:41–51. DOI: https://doi.org/10.1016/S0092-8674(00)80713-8, PMID: 10199401

Yanagitani K, Juszkiewicz S, Hegde RS. 2017. UBE2O is a quality control factor for orphans of multiprotein complexes. *Science* 357:472–475. DOI: https://doi.org/10.1126/science.aan0178, PMID: 28774922

Yang Z, Yik JH, Chen R, Pezda AC, Samford CS, Zhou Q. 2004. A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb. *Molecular and Cellular Biology* 24:5094–5105. DOI: https://doi.org/10.1128/MCB.24.12.5094-5105.2004, PMID: 15169877

Yu X, Yu Y, Liu B, Luo K, Zhou Q. 2001. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. *Nature* 414:317–322. DOI: https://doi.org/10.1038/35104575, PMID: 11713532

Yik JH, Chen R, Pezda AC, Samford CS, Zhou Q. 2004. A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb. *Molecular and Cellular Biology* 24:5094–5105. DOI: https://doi.org/10.1128/MCB.24.12.5094-5105.2004, PMID: 15169877

Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. *Science* 302:1056–1060. DOI: https://doi.org/10.1126/science.1089591, PMID: 14564014

Yuan WC, Lee YR, Lin SY, Chang LY, Tan YP, Hung CC, Kuo JC, Liu CH, Lin MY, Xu M, Chen ZJ, Chen RH. 2014. K33-Linked polyubiquitination of coronin 7 by Cul3-KLHL20 ubiquitin E3 ligase regulates protein trafficking. *Molecular Cell* 54:586–600. DOI: https://doi.org/10.1016/j.molcel.2014.03.035, PMID: 24768539

Zeitlinger J, Stark A, Kellis M, Hong JW, Nechaev S, Levine M, Young RA, Young RA. 2007. RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo. *Nature Genetics* 39:1512–1516. DOI: https://doi.org/10.1038/ng.2007.26, PMID: 17994019

Zhang X, Zhang J, Bauer A, Zhang L, Selinger DW, Lu CX, Ten Dijke P. 2013a. Fine-tuning BMP7 signalling in adipogenesis by UBE2O/E2-230K-mediated monoubiquitination of SMAD6. *The EMBO Journal* 32:996–1007. DOI: https://doi.org/10.1038/embj.2013.38, PMID: 23455153

Zhang X, Zhang J, Zhang L, van Dam H, ten Dijke P. 2013b. UBE2O negatively regulates TRAF6-mediated NF-κB activation by inhibiting TRAF6 polyubiquitination. *Cell Research* 23:366–377. DOI: https://doi.org/10.1038/cr.2013.21, PMID: 23381138